Predictive Oncology Launches Website Highlighting AI-Powered Cancer Research Advancements
19 October 2021 - 11:30PM
Predictive Oncology, an oncology and cancer research company using
big data and machine learning to improve pharmaceutical development
and predictive treatment outcomes, launched a website today that
emphasizes its role in advancing its mission.
The website features information about Predictive Oncology and
its subsidiaries, Helomics, Soluble Biotech and TumorGenesis which
are all integral to the overarching goal of eliminating cancer by
predicting treatment outcomes and aiding in the development and
optimization of cancer drugs.
“The website redesign is really intended to showcase the great
work that all these teams have been doing, and emphasize what
they’re all contributing to the same grand mission under the
Predictive Oncology banner,” said J. Melville Engle, CEO and
Chairman of the Board of Predictive Oncology. “Putting an end to
cancer is a team effort. We need the analytical capabilities of
Helomics and TumorGenesis to help expedite the development of new
cancer treatments and we need the expertise of Soluble Biotech to
optimize those treatments. Each is mission-critical to our end goal
of equipping healthcare providers with what they need to take the
fight to cancer and win.”
Here’s a closer look at each of Predictive Oncology’s
subsidiaries and how they’re contributing to advancing cancer
research and saving lives:
- Helomics: Helomics maintains a database that
includes information on 137 types of tumors and more than 15 years
of treatment outcome data spanning more than 150,000 clinical
cases. Helomics relies on proprietary artificial intelligence
software, known as the Computational Research Engine (CoRE™), to
analyze this rich set of data and personalize cancer therapies for
patients. It can also help drive the development of new targeted
therapies in collaborations with pharmaceutical companies, finding
effective treatments more quickly and helping them get to clinical
trials.
- Soluble Biotech: Soluble Biotech is a provider
of soluble and stable formulations for proteins including vaccines,
antibodies, large and small proteins, and protein complexes.
Soluble Biotech can help decrease the cost, time, and demand on
resources conventionally needed to optimize formulations, cutting
the average time down from one year to just three months.
- TumorGenesis: TumorGenesis enables researchers
to better study cancer cells found in tumors of the blood and all
organ systems. TumorGenesis achieves this by growing cancer cells
in the lab while retaining the unique DNA/RNA and proteomic
signatures that would exist inside a patient’s body. In this way,
TumorGenesis offers a granular view of the tumor -- and the
information needed to effectively treat the patient’s cancer.
Currently, TumorGenesis is focused on studying ovarian cancer
tumors, covering 25 ovarian cancer cell lines representing 90% of
ovarian cancers.
“Eliminating cancer may seem like a lofty goal, and indeed such
a complex disease isn’t going to be cured overnight,” said Engle.
“But, with modern technology and the power of artificial
intelligence, we have at our disposal some of the most potent tools
to solve the challenges facing us in cancer research. Now that we
can contextualize and cross-reference hundreds of thousands of case
studies against detailed information about each and every tumor we
have received, we can ensure our treatments are tailor-made to be
most effective for each and every patient.”
About Predictive Oncology
Predictive Oncology Inc. (NASDAQ: POAI) is a knowledge-driven
company focused on applying artificial intelligence (AI) to develop
personalized cancer therapies, which can lead to more effective
treatments and improved patient outcomes. Using artificial
intelligence, Predictive Oncology utilizes a database of 150,000+
cancer tumors, categorized by patient type, against drug compounds
to determine optimal therapies to be used to ultimately eliminate
cancer.
As the drug discovery community realizes, a genomics-based
approach to cancer research and drug development is insufficient to
achieve the promise of personalized therapeutics. Predictive
Oncology instead takes a multiomic approach, which considers the
vast multitude of factors that make each cancer unique. Rather than
operating based on the equivalent of a birds’ eye view, Predictive
Oncology makes possible a more personalized and effective approach
to cancer research and treatment.
Forward-Looking Statements
Certain matters discussed in this release contain
forward-looking statements. These forward-looking statements
reflect our current expectations and projections about future
events and are subject to substantial risks, uncertainties and
assumptions about our operations and the investments we make. All
statements, other than statements of historical facts, included in
this press release regarding our strategy, future operations,
future financial position, future revenue and financial
performance, projected costs, prospects, plans and objectives of
management are forward-looking statements. The words “anticipate,”
“believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “would,”
“target” and similar expressions are intended to identify
forward-looking statements, although not all forward-looking
statements contain these identifying words. Our actual future
performance may materially differ from that contemplated by the
forward-looking statements as a result of a variety of factors
including, among other things, factors discussed under the heading
“Risk Factors” in our filings with the SEC. Except as expressly
required by law, the Company disclaims any intent or obligation to
update these forward-looking statements.
Investor Relations Contact:
Landon Capital Keith Pinder (404)
995-6671kpinder@landoncapital.netMedia
Contact:media@predictive-oncology.com
Predictive Oncology (NASDAQ:POAI)
Historical Stock Chart
From Apr 2024 to May 2024
Predictive Oncology (NASDAQ:POAI)
Historical Stock Chart
From May 2023 to May 2024